Selected article for: "acute diffuse and admission time"

Author: Cui, Xiaoyang; Yu, Xin; Wu, Xiaojing; Huang, Linna; Tian, Ye; Huang, Xu; Zhang, Zeyu; Cheng, Zhenshun; Guo, Qiang; Zhang, Yi; Cai, Ying; Zhan, Qingyuan
Title: Acute Kidney Injury in Patients with the Coronavirus Disease 2019: A Multicenter Study
  • Cord-id: chiadufa
  • Document date: 2020_7_24
  • ID: chiadufa
    Snippet: INTRODUCTION: Severe acute respiratory viral infections are frequency accompanied by multiple organ dysfunction, including acute kidney injury (AKI). In December 2019, the coronavirus disease 2019 (COVID-19) outbreak began in Wuhan, Hubei Province, China, and rapidly spread worldwide. While diffuse alveolar damage and acute respiratory failure are the main features of COVID-19, other organs may be involved, and the incidence of AKI is not well described. We assessed the incidence and clinical ch
    Document: INTRODUCTION: Severe acute respiratory viral infections are frequency accompanied by multiple organ dysfunction, including acute kidney injury (AKI). In December 2019, the coronavirus disease 2019 (COVID-19) outbreak began in Wuhan, Hubei Province, China, and rapidly spread worldwide. While diffuse alveolar damage and acute respiratory failure are the main features of COVID-19, other organs may be involved, and the incidence of AKI is not well described. We assessed the incidence and clinical characteristics of AKI in patients with laboratory-confirmed COVID-19 and its effects on clinical outcomes. METHODS: We conducted a multicenter, retrospective, observational study of patients with COVID-19 admitted to two general hospitals in Wuhan from 5 January 2020 to 21 March 2020. Demographic data and information on organ dysfunction were collected daily. AKI was defined according to the KDIGO clinical practice guidelines. Early and late AKI were defined as AKI occurring within 72 h after admission or after 72 h, respectively. RESULTS: Of the 116 patients, AKI developed in 21 (18.1%) patients. Among them, early and late AKI were found in 13 (11.2%) and 8 (6.9%) patients, respectively. Compared with patients without AKI, patients with AKI had more severe organ dysfunction, as indicated by a higher level of disease severity status, higher sequential organ failure assessment (SOFA) score on admission, an increased prevalence of shock, and a higher level of respiratory support. Patients with AKI had a higher SOFA score on admission (4.5 ± 2.1 vs. 2.8 ± 1.4, OR 1.498, 95% CI 1.047–2.143) and greater hospital mortality (57.1% vs. 12.6%, OR 3.998, 95% CI 1.088–14.613) than patients without AKI in both the univariate and multivariate analyses. Patients with late AKI, but not those with early AKI, had a significantly prolonged length of stay (19.6 vs. 9.6 days, p = 0.015). CONCLUSION: Our findings show that admission SOFA score was an independent risk factor for AKI in COVID-19 patients, and patients with AKI had higher in-hospital mortality. Moreover, AKI development after 72 h of admission was related to prolonged hospitalization time.

    Search related documents:
    Co phrase search for related documents
    • acid test result and lymphocyte count: 1
    • acute aki kidney injury and long period: 1, 2
    • acute aki kidney injury and lung cancer: 1, 2
    • acute aki kidney injury and lung disease: 1, 2, 3, 4, 5
    • acute aki kidney injury and lym lymphocyte count: 1
    • acute aki kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute cytokine storm respiratory distress syndrome and lung cancer: 1, 2, 3
    • acute cytokine storm respiratory distress syndrome and lung disease: 1, 2, 3, 4
    • acute cytokine storm respiratory distress syndrome and lymphocyte count: 1
    • acute respiratory viral infection and lung addition: 1
    • acute respiratory viral infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • admission score and lung cancer: 1
    • admission score and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
    • admission score and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • admission serum creatinine and lung disease: 1
    • admission serum creatinine and lymphocyte count: 1, 2
    • admission sofa score and lymphocyte count: 1, 2, 3, 4
    • liver renal and lung cancer: 1, 2, 3, 4
    • liver renal and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9